Generic Name: Mannitol (Diuretic)
Class: Osmotic Diuretics
VA Class: CV709
CAS Number: 69-65-8
Introduction
An osmotic diuretic.a b
Uses for Osmitrol
Oliguric Acute Renal Failure
Used to promote diuresis for the prevention and/or treatment of the oliguric phase of acute renal failure, which may occur after massive hemorrhage, trauma, shock, burns, transfusion reactions caused by mismatched blood, or major surgery before there is evidence of tubular necrosis or multiple vascular thrombosis.a b
Has been used to reduce nephrotoxicity caused by amphotericin B.a
Has no effect and may be harmful if used after tubular necrosis and irreversible renal failure become established.a b
Reduction of Intracranial Pressure
Used prior to and during neurosurgery to reduce greatly increased intracranial pressure and for the treatment of cerebral edema.a b Also may be used for early treatment of cerebral edema in patients with diabetic ketoacidosis or in those in hypoglycemic coma who fail to respond to increases of blood glucose concentrations.a
Reduction of Intraocular Pressure
Used to reduce elevated intraocular pressure (IOP) when the pressure cannot be lowered by other means.a b Especially useful for treating acute episodes of angle-closure, absolute, or secondary glaucoma and for lowering IOP prior to intraocular surgery.a
Urinary Excretion of Toxins
Used alone or with other diuretics (e.g., furosemide, ethacrynic acid) to promote the urinary excretion of toxins (e.g., aspirin or other salicylates, some barbiturates, bromides, imipramine) as an adjunct to usual treatment regimens in patients with severe intoxications.a b
Transurethral Prostatic Resection and Transurethral Prostatectomy
Used as an irrigating solution in transurethral prostatic resectiond to minimize the hemolytic effects of water, the entrance of hemolyzed blood into the circulation, and the resulting hemoglobinemia which is considered a major factor in producing serious renal complications.a
Also has been administered IV before, during, and after transurethral prostatectomy† to maintain urine output, promote rapid excretion of absorbed irrigants, and reduce the need for postoperative irrigation.a
Hyperuricemia
Has been used to promote excretion of uric acid and prevent hyperuricemia and/or uric acid nephropathy† in patients who develop uricemia following chemotherapy or radiation therapy for leukemia or lymphoma.a
Ciguatera Toxicity
Has been used as initial therapy, in combination with other supportive therapy, to reverse neurologic and neurosensory manifestations as well as GI manifestations of ciguatera fish poisoning†.102 a
Edema and Ascites
Has been used alone or in conjunction with other diuretics to promote diuresis for the supportive treatment of edema and ascites† of nephrotic, cirrhotic, or cardiac origin.a
Osmitrol Dosage and Administration
General
Dosage, concentration of solution, and rate of administration vary with the condition being treated and the patient’s fluid requirements, urinary output, and response to the drug.a
Do not administer drug until adequacy of patient's renal function and urine flow have been established.a
Replace fluids, plasma, blood, and electrolytes prior to initiating therapy in patients with shock with oliguria and rising BUN.a
Administration
Administer mannitol injection IV.a b Administer sorbitol-mannitol irrigation solution by transurethral instillation.d
IV Administration
For drug compatibility information, see Compatibility under Stability.
Administer by IV infusion using an administration set with a filter.a b
When used in surgical procedures to prevent oliguric acute renal failure, administration may be initiated before or immediately following surgery and may be continued postoperatively.a
When used preoperatively to reduce IOP, administer 1–1.5 hours prior to surgery in order to achieve maximum reduction of pressure before surgery.a b
Test Dose
Administer a test dose to patients with marked oliguria or suspected inadequate renal function to establish renal response before therapy is initiated.a b
A response is considered adequate if at least 30–50 mL of urine per hour is excreted over the next 2–3 hours.a b
If an adequate response is not attained, a second test dose may be given.a b
If a satisfactory response is not obtained after the second test dose, reevaluate patient, and mannitol should not be used.a b
Rate of Administration
Test dose in adults and children >12 years of age: Infuse over a period of 3–5 minutes to produce urine flow of ≥30–50 mL/hour.a b
Treatment of oliguria in adults: Infuse over 90 minutes to several hours.a
Cerebral or ocular edema in children >12 years of age: Usually, infuse over 30–60 minutes.a
Reduction of intracranial or IOP in adults: Usually, infuse over 30–60 minutes.a
Edema and ascites† in adults and children >12 years of age: Has been infused over 2–6 hours.a
Transurethral Irrigation
Sorbitol-mannitol irrigation solution is for urologic irrigation only; do not use for injection.d
Administer only by transurethral instillation using appropriate and disposable urologic instrumentation.d
Placing the flexible irrigation container >60 cm above the operating table may increase intravascular absorption of irrigation solution.d
Dosage
Pediatric Patients
Oliguric Acute Renal Failure
Test dose
IV
Children >12 years of age: 0.2 g/kg or 6 g/m2 as a single dose.a
Therapeutic purpose
IV
Children >12 years of age: 2 g/kg or 60 g/m2.a
Cerebral or Ocular Edema
IV
Children >12 years of age: 2 g/kg or 60 g/m2 administered as a 15 or 20% solution.a
Urinary Excretion of Toxins
IV
Children >12 years of age: 2 g/kg or 60 g/m2 administered as a 5 or 10% solution as needed.a
Edema and Ascites†
IV
Children >12 years of age: 2 g/kg or 60 g/m2 administered as a 15 or 20% solution.a
Adults
Usual Dosage
IV
20–100 g administered in a 24-hour period.b
Test Dose
IV
Approximately 0.2 g/kg or 12.5 g infused IV as a 15 or 20% solution (usually 100 or 75 mL of a 15 or 20% solution, respectively).a b
Oliguric Acute Renal Failure
Prevention
IV
50–100 g as a 5, 10, or 15% solution.a b Generally, a concentrated solution is administered initially followed by a 5 or 10% solution.a
Treatment of Oliguria
IV
100 g infused IV as a 15 or 20% solution.a b
Management of Nephrotoxicity Associated with Amphotericin B
IV
12.5 g administered immediately before and after each dose of amphotericin B.a
Reduction of Intracranial Pressure
IV
Usually, 0.25 g/kg administered not more frequently than every 6–8 hours will achieve a maximum reduction of intracranial pressure.b Alternatively, 1.5–2 g/kg infused IV as a 15, 20, or 25% solution.a
A satisfactory reduction in intracranial pressure can be achieved with an osmotic gradient between blood and CSF of approximately 10 mOsmol.b
Reduction of IOP
IV
Usually, 1.5–2 g/kg infused IV as a 15, 20, or 25% solution.a b
Some clinicians have recommended as little as 1 g or as much as 3.2 g/kg infused IV as a 15, 20, or 25% solution.a
Urinary Excretion of Toxins
IV
In general, maintain a urinary output of >100 mL/hour, but preferably 500 mL/hour, and a positive fluid balance of 1–2 L.a
Initially, 25 g, followed by infusion of a solution at a rate that will maintain a urinary output of ≥100 mL/hour.a
In barbiturate poisoning, initially 0.5 g/kg, followed by administration of a 5 or 10% solution at a rate to maintain the desired urine output.a
Alternatively, administer 1 L of a 10% solution during the first hour.a Measure urine volume and pH and calculate cumulative fluid balance at the end of the first hour and subsequent 2-hour periods.a If positive fluid balance is 1–2 L, administer 1 L of a 10% solution over the next 2 hours.a If positive fluid balance is <1 L, replace mannitol with 1 L of (1/6) M sodium lactate over the next 2 hours (if urine pH <7) or 1 L of 0.9% sodium chloride over 2 hours (if urine pH >7).a If the positive fluid balance is >2 L, administer 10% mannitol at the slowest possible rate.a IV administration of furosemide recommended if the positive fluid balance >2.5 L.a
Transurethral Prostatic Resection
Urogenital Irrigation
Administer a sufficient volume of sorbitol-mannitol irrigation solution; volume determined at the discretion of clinician.d
Hyperuricemia†
IV
50 g/m2 has been given in 24 hours.a
Ciguatera Toxicity†
IV
1 g/kg.102
Edema and Ascites†
IV
100 g infused IV as a 10–20% solution.a
Special Populations
Geriatric Patients
Select dosage with caution, starting at the low end of the dosing range, because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.a b
Cautions for Osmitrol
Contraindications
In patients with well-established anuria caused by severe renal diseasea b or impaired renal function who do not respond to 2 test doses.a b (See Test Dose under Dosage and Administration.)
Severe pulmonary congestion or frank pulmonary edema.a b
Severe CHF.a
Severe dehydration.a b
Metabolic edema associated with capillary fragility or membrane permeability not associated with renal, cardiac, or hepatic disease.a
Active intracranial bleeding except during craniotomy.a b
Progressive renal disease or dysfunction, including increasing oliguria and azotemia, or progressive heart failure or pulmonary congestion occurring after institution of mannitol therapy.a b
Warnings/Precautions
Warnings
Fluid and Electrolyte Imbalance
Risk of serious electrolyte disturbances (e.g., hyponatremia, hypernatremia, hypokalemia, hyperkalemia); may be severe enough to alter acid-base balance or depress respiration.a b Thiazides may be used if hypernatremia or hyperosmolality occurs.a
Accumulation of mannitol caused by inadequate urinary output or rapid administration of large doses may result in overexpansion of extracellular fluid and circulatory overload causing signs and symptoms of water intoxication.a Overhydration may be corrected by hemodialysis or administration of a potent diuretic (e.g., furosemide).a
If urine output declines during administration, review patient’s clinical status and discontinue mannitol if necessary.a
Stop or slow mannitol if central venous pressure rises or there is any other evidence of circulatory overload.a Fluid administration should not exceed 1 L/day in excess of urinary output.a
Sustained diuresis may result in intensification of preexisting hemoconcentration; also may result in hypovolemia which reduces glomerular filtration rate and enhances the reabsorption of sodium and water.a b
Prevent or treat volume and electrolyte depletion by administering dilute mannitol solutions with sodium chloride added or by alternating each liter of mannitol solution with a liter of sodium chloride injection to which 40 mEq of potassium chloride has been added.a If the threat of renal shutdown exists, potassium supplementation should be administered subsequent to, but not concomitantly with, mannitol.a
Cardiovascular Effects
Overexpansion of extracellular fluid (see Fluid and Electrolyte Imbalance under Cautions) may result in pulmonary edema and fulminating CHF, especially in patients with diminished cardiac reserve.a b Carefully evaluate cardiovascular status prior to administration.b
Renal Effects
Possible irreversible vacuolar nephrosis.a b
General Precautions
Pseudoagglutination
Possible pseudoagglutination if electrolyte-free mannitol solutions are given concomitantly with blood.a If blood must be given simultaneously with mannitol, add ≥20 mEq of sodium chloride to each liter of mannitol solution.a
Patient Monitoring
Carefully monitor for fluid and electrolyte imbalances.a b
Monitor urine output; serum sodium and potassium concentrations; central venous pressure; degree of hemoconcentration or hemodilution; and renal, cardiac, and pulmonary function.a b
Use of Fixed-combination Urogenital Irrigation Solution
When sorbitol-mannitol irrigation solution is used, consider the cautions, precautions, and contraindications associated with sorbitol.d
Specific Populations
Pregnancy
Category C.b d
Lactation
Not known whether mannitol is distributed into milk.b Caution advised if mannitol is used.b
Pediatric Use
Safety and efficacy of mannitol injections not established in children <12 years of age.b
Safety and efficacy of sorbitol-mannitol irrigation solution not established.d
Geriatric Use
Insufficient experience in patients ≥65 years of age in clinical trials;b however, response does not appear to differ from that in younger adults.b Select dosage with caution due to greater frequency of decreased hepatic, renal, and/or cardiac function and of concomitant disease and drug therapy observed in the elderly.b
Substantially eliminated by kidneys; assess renal function periodically since geriatric patients more likely to have decreased renal function.b
Renal Impairment
Substantially eliminated by kidneys; increased risk of toxic reactions.b
Administer a test dose to patients with severe renal impairment. (See Test Dose under Dosage and Administration.)
Common Adverse Effects
Fluid and electrolyte imbalance.a b
Interactions for Osmitrol
Specific Drugs
Drug
|
Interaction
|
Comments
|
|---|
Lithium
|
Increased urinary excretion of lithiuma
|
Observe for possible impairment of response to lithiuma
|
Osmitrol Pharmacokinetics
Absorption
Bioavailability
Has been thought not to be absorbed when administered orally; however, about 17% of an oral dose was excreted unchanged in urine.a
Absorbed into systemic circulation following transurethral instillation as sorbitol-mannitol irrigation solution.d
Onset
Following IV administration, diuresis generally occurs within 1–3 hours, lowering of elevated CSF pressure occurs within 15 minutes, and lowering of elevated intraocular pressure occurs within 30–60 minutes.a
Duration
Lowering of elevated CSF pressure and elevated IOP persists for 3–8 and 4–6 hours, respectively, after infusion is stopped.a
Distribution
Extent
Following IV administration, mannitol remains confined to the extracellular compartment; does not cross the blood-brain barrier unless very high concentrations are present in the plasma or the patient has acidosis; and does not penetrate the eye.a
Elimination
Metabolism
Slightly metabolized to glycogen in the liver.a b
Elimination Route
Freely filtered by the glomeruli, with <10% tubular reabsorption; not secreted by tubular cells.a
Excreted principally in urine as unchanged drug.a
Half-life
100 minutes.a
Special Populations
Decreased clearance in patients with renal disease in which glomerular function is impaired.a
Decreased clearance in patients with conditions that impair small vessel circulation (e.g., CHF, cirrhosis with ascitic accumulation, shock, dehydration).a
Stability
Storage
Parenteral
Powder for Injection
15–30°C; do not freeze.a
Mannitol solutions ≥15% concentrations may crystallize when exposed to low temperatures.a b If crystallization occurs, warm the solution to 70°C and periodically shake vigorously.b Cool solution to room temperature prior to administration.b Do not use the solution if all crystals cannot be completely dissolved.a
Urogenital Irrigation
Solution for Irrigation
25°C.d Do not freeze; avoid excessive heat.d
Compatibility
For information on systemic interactions resulting from concomitant use, see Interactions.
Drug Compatibility
Admixture CompatibilityHID
Compatible
|
|---|
Amikacin sulfate
|
Bretylium tosylate
|
Cefoxitin sodium
|
Cimetidine HCl
|
Cisplatin
|
Dopamine HCl
|
Fosphenytoin sodium
|
Furosemide
|
Gentamicin sulfate
|
Metoclopramide HCl
|
Nizatidine
|
Ofloxacin
|
Ondansetron HCl
|
Sodium bicarbonate
|
Tobramycin sulfate
|
Verapamil HCl
|
Incompatible
|
|---|
Imipenem–cilastatin sodium
|
Meropenem
|
Variable
|
|---|
Etoposide with cisplatin and potassium chloride
|
Levofloxacin
|
Y-Site CompatibilityHID
Compatible
|
|---|
Allopurinol sodium
|
Amifostine
|
Amphotericin B cholesteryl sulfate complex
|
Aztreonam
|
Bivalirudin
|
Cladribine
|
Docetaxel
|
Etoposide phosphate
|
Fenoldopam mesylate
|
Fludarabine phosphate
|
Fluorouracil
|
Gallium nitrate
|
Gemcitabine HCl
|
Hetastarch in lactated electrolyte injection (Hextend)
|
Idarubicin HCl
|
Lansoprazole
|
Linezolid
|
Melphalan HCl
|
Ondansetron HCl
|
Oxaliplatin
|
Paclitaxel
|
Pemetrexed disodium
|
Piperacillin sodium–tazobactam sodium
|
Propofol
|
Remifentanil HCl
|
Sargramostim
|
Teniposide
|
Thiotepa
|
Vinorelbine tartrate
|
Incompatible
|
|---|
Cefepime HCl
|
Doxorubicin HCl liposome injection
|
Filgrastim
|
Pantoprazole sodium
|
ActionsActions
Induces diuresis mainly by elevating the osmotic pressure of the glomerular filtrate, which hinders the tubular reabsorption of water and solutes and increases the excretion of sodium.a b
Increased renal blood flow resulting from dilation of vascular segments between the renal artery and glomeruli, lowered renal vascular resistance, and reduced blood viscosity also may contribute to the diuretic effect.a
Increases excretion of potassium, chloride, calcium, phosphorus, lithium, magnesium, urea, and uric acid.a
Increases extracellular fluid volume, plasma volume, and circulation time and dilutes extracellular stores of sodium by causing water to be drawn from cells to extracellular fluid and from erythrocytes to plasma.a Fluid shifts result in reduction of cerebral edema (by reduction in brain mass) and lowering of CSF pressure.a b Reduction of elevated IOP associated with withdrawal of fluids from anterior chamber of the eye.a b
Prevents or reverses acute functional renal failure by reversing the acute reductions in renal blood flow, glomerular filtration rate, urine flow, and sodium excretion that may occur after trauma.a
Protects kidneys from nephrotoxins by preventing toxins from becoming concentrated in the tubular fluid.a
Advice to Patients
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.a
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.a
Importance of informing patients of other important precautionary information. (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Mannitol
Routes
|
Dosage Forms
|
Strengths
|
Brand Names
|
Manufacturer
|
|---|
Bulk
|
Powder
|
|
|
|
Parenteral
|
Injection
|
5%*
|
Mannitol Injection
|
Hospira
|
|
|
|
Osmitrol
|
Baxter
|
|
|
10%*
|
Mannitol Injection
|
Hospira
|
|
|
|
Osmitrol
|
Baxter
|
|
|
15%*
|
Mannitol Injection
|
Hospira
|
|
|
|
Osmitrol
|
Baxter
|
|
|
20%*
|
Mannitol Injection
|
Braun, Hospira
|
|
|
|
Osmitrol
|
Baxter
|
|
|
25%*
|
Mannitol Injection
|
Abraxis, American Regent, Hospira
|
Mannitol Combinations
Routes
|
Dosage Forms
|
Strengths
|
Brand Names
|
Manufacturer
|
|---|
Urogenital
|
Solution
|
0.54% with Sorbitol 2.7%
|
Sorbitol-Mannitol Irrigating Solution
|
Hospira
|
Disclaimer
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions August 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
† Use is not currently included in the labeling approved by the US Food and Drug Administration.
References
100. Goldwasser P, Fotino S. Acute renal failure following massive mannitol infusion: appropriate response of tubuloglomerular feedback? Arch Intern Med. 1984; 144:2214-6.
101. Whelan TV, Bacon ME, Madden M et al. Acute renal failure associated with mannitol intoxication: report of a case. Arch Intern Med. 1984; 144:2053-5. [IDIS 191007] [PubMed 6435559]
102. Palafox NA, Jain LG, Pinano AZ et al. Successful treatment of ciguatera fish poisoning with intravenous mannitol. JAMA. 1988; 259:2740-2. [IDIS 240955] [PubMed 3128666]
a. AHFS Drug Information 2005. McEvoy, GK, ed. Mannitol. Bethesda, MD: American Society of Health-System Pharmacists; 2005:2586-9.
b. Baxter Healthcare. Osmitrol (mannitol injection USP) prescribing information. Deerfield, IL: 2005 Aug.
HID. Trissel LA. Handbook on injectable drugs. 14th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1039-44.
d. Hospira. Sorbitol-Mannitol Irrigation prescribing information. Lake Forest, IL: 2004 Aug.
More Osmitrol resources
- Osmitrol Side Effects (in more detail)
- Osmitrol Use in Pregnancy & Breastfeeding
- Osmitrol Drug Interactions
- Osmitrol Support Group
- 0 Reviews for Osmitrol - Add your own review/rating
- Osmitrol Prescribing Information (FDA)
- Osmitrol MedFacts Consumer Leaflet (Wolters Kluwer)
- Aridol Consumer Overview
- Aridol Advanced Consumer (Micromedex) - Includes Dosage Information
Compare Osmitrol with other medications
